January 28, 2025

FDA Approves Enhertu for Metastatic, HR-Positive, HER2-Low or -Ultralow Breast Cancer

Enhertu, a HER2-directed antibody-drug conjugate, was approved by the U.S. Food and Drug Administration for pretreated patients with metastatic HR-positive, HER2-low or HER2-ultralow breast cancer based on results from the DESTINY-Breast06 trial.

June 01, 2024

Antibody-Drug Conjugate Plus Checkpoint Inhibitor for PD-L1–Positive, HR-Positive/HER2-Negative Breast Cancer

The phase II SACI-IO HR+ trial—results of which were presented at the 2024 ASCO Annual Meeting—was designed to evaluate whether sacituzumab govitecan-hziy and pembrolizumab work synergistically in pat...

July 16, 2024

A Role for Avelumab in Triple-Negative Breast Cancer?

In patients with triple-negative early breast cancer deemed to be at high risk for recurrence, 1 year of adjuvant avelumab did not significantly improve disease-free survival but did significantly imp...

June 03, 2024

USP1 Inhibitor in Metastatic Solid Tumors

The first-in-class ubiquitin-specific peptidase 1 (USP1) inhibitor RO7623066 showed a positive safety profile as a single agent and signs of early antitumor activity in patients with advanced solid tu...

June 03, 2024

Study Including Only Black Patients With Breast Cancer Compares Rates of Taxane-Induced Peripheral Neuropathy

New findings suggest that docetaxel may be considered the preferred treatment over paclitaxel for Black patients with early-stage breast cancer. While the EAZ171 trial focused specifically on Black pe...

June 05, 2024

New Study Highlights Benefits of Stepped Palliative Care in Advanced Lung Cancer

Researchers have uncovered the effectiveness of more scalable ways of delivering palliative care in patients with advanced lung cancer, according to new findings presented at the 2024 ASCO Annual Meet...

July 25, 2024

Triplet Combination Improves Survival in Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Third-Line Setting

The anti-CD30 antibody-drug conjugate brentuximab vedotin is a standard of care for certain types of lymphomas, including classical Hodgkin lymphoma in combination with multiagent chemotherapy. Brentu...

June 01, 2024

American Cancer Society and ASCO Announce Expanded Patient-Centered Online Collaboration

The American Cancer Society and ASCO today announced an expanded collaboration to make it simpler for patients to find authoritative cancer information online. The partnership will create one of the l...

June 02, 2024

Telehealth Shown to Be Effective for Palliative Care Delivery in Patients With Advanced Lung Cancer

New research presented at the 2024 ASCO Annual Meeting reinforces the telehealth delivery of palliative care as an effective alternative to in-person visits for patients with advanced lung cancer, pro...

July 10, 2024

Novel Antibody-Drug Conjugate Extends Survival vs Chemotherapy in Triple-Negative Breast Cancer

The antibody-drug conjugate sacituzumab tirumotecan extended overall survival as well as progression-free survival vs chemotherapy in patients with previously treated triple-negative breast cancer, ac...